NASDAQ:CNTB Connect Biopharma (CNTB) Stock Price, News & Analysis $1.28 -0.01 (-0.78%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.29 +0.01 (+0.78%) As of 09/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Connect Biopharma Stock (NASDAQ:CNTB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Connect Biopharma alerts:Sign Up Key Stats Today's Range$1.25▼$1.3250-Day Range$1.17▼$2.7652-Week Range$1.06▼$3.82Volume1.27 million shsAverage Volume1.88 million shsMarket Capitalization$80.60 millionP/E RatioN/ADividend YieldN/APrice Target$7.29Consensus RatingModerate Buy Company Overview Connect Biopharma Holdings Limited (NASDAQ:CNTB) is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and immune-mediated diseases. The company’s research is based on insights into T-cell biology and aims to address conditions with significant unmet medical needs, including inflammatory bowel disease and dermatological disorders. Connect Biopharma’s pipeline has included CBP-201, an antibody targeting the interleukin-4 receptor alpha pathway, and CBP-307, an oral sphingosine-1-phosphate receptor modulator. These investigational therapies have been studied in conditions such as atopic dermatitis, Crohn’s disease and ulcerative colitis. As clinical-stage products, the candidates remain subject to clinical testing and regulatory review and may not ultimately receive approval. Founded in 2012, Connect Biopharma has operated across the United States and China, combining drug-discovery and clinical-development capabilities in both regions. The company was founded by Dr. Zheng Wei, who has served as its chief executive officer. Its shares have traded on the Nasdaq under the symbol CNTB since the company’s public listing in 2021.AI Generated. May Contain Errors. Read More Connect Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreCNTB MarketRank™: Connect Biopharma scored higher than 65% of companies evaluated by MarketBeat, and ranked 276th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingConnect Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialConnect Biopharma has a consensus price target of $7.29, representing about 469.2% upside from its current price of $1.28.Amount of Analyst CoverageConnect Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Connect Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Connect Biopharma are expected to grow in the coming year, from ($1.10) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Connect Biopharma is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Connect Biopharma is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioConnect Biopharma has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Connect Biopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.08% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 4.17.Change versus previous monthShort interest in Connect Biopharma has recently increased by 9.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldConnect Biopharma does not currently pay a dividend.Dividend GrowthConnect Biopharma does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.14 News SentimentConnect Biopharma has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Connect Biopharma this week, compared to 3 articles on an average week.Search Interest5 people have searched for CNTB on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows5 people have added Connect Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Connect Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Connect Biopharma's insider trading history. Receive CNTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTB Stock News HeadlinesAnalysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Connect Biopharma Holdings (CNTB)September 18 at 9:14 PM | theglobeandmail.comCanaccord Genuity Group Has Lowered Expectations for Connect Biopharma (NASDAQ:CNTB) Stock PriceSeptember 18 at 1:36 AM | americanbankingnews.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. | Base Camp Trading (Ad)Connect Biopharma (NASDAQ:CNTB) Earns "Buy" Rating from BTIG ResearchSeptember 17 at 1:43 AM | americanbankingnews.comConnect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations TranscriptSeptember 16 at 4:00 AM | seekingalpha.comConnect Biopharma rademikibart phase 2 data shows lung function improvement but primary endpoint misses significanceSeptember 15, 2026 | msn.comWhy Is Connect Biopharma Stock Trading Lower on Tuesday?September 15, 2026 | benzinga.comConnect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and ...September 15, 2026 | finance.yahoo.comSee More Headlines CNTB Stock Analysis - Frequently Asked Questions How have CNTB shares performed this year? Connect Biopharma's stock was trading at $2.82 at the beginning of the year. Since then, CNTB shares have decreased by 54.6% and is now trading at $1.28. How were Connect Biopharma's earnings last quarter? Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) released its earnings results on Wednesday, August, 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.04. The business had revenue of $2.75 million for the quarter, compared to analysts' expectations of $0.74 million. When did Connect Biopharma IPO? Connect Biopharma (CNTB) raised $180 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 11,250,000 shares at a price of $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO. How do I buy shares of Connect Biopharma? Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Connect Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Connect Biopharma investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Builders FirstSource (BLDR) and Company Calendar Last Earnings8/12/2026Today9/18/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CNTB's financial health is in the Green zone, according to TradeSmith. CNTB has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CNTB CIK1835268 Webwww.connectbiopharm.com Phone(858) 727-1040Fax+1 8586147007Employees64Year Founded2012Price Target and Rating Average Price Target for Connect Biopharma$7.29 High Price Target$10.00 Low Price Target$4.00 Potential Upside/Downside+469.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.48 million Net MarginsN/A Pretax Margin-2,329.67% Return on Equity-165.41% Return on Assets-121.58% Debt Debt-to-Equity Ratio0.01 Current Ratio2.37 Quick Ratio2.37 Sales & Book Value Annual Sales$60 thousand Price / Sales1,343.36 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book1.71Miscellaneous Outstanding Shares62,970,000Free Float48,742,000Market Cap$80.60 million OptionableOptionable Beta-0.23 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CNTB) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTB Stock Alerts